Last reviewed · How we verify
NCT06959784
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
Phase 4 trial testing semaglutide in Diabetes Mellitus in 142 participants. Enrolling by invitation.
31 December 2026
Quick facts
| Lead sponsor | China-Japan Friendship Hospital |
|---|---|
| Phase | Phase 4 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 142 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- semaglutide (semaglutide) — full drug profile →
- Metformin (metformin) — full drug profile →
Conditions studied
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Cerebrovascular Disease — all drugs for Cerebrovascular Disease →
Sponsor
China-Japan Friendship Hospital
Who can join
Adults 30 to 70, any sex, with Diabetes Mellitus or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study used the diabetes prevention and follow-up research queue in Daqing and the public database of UKbiobank to evaluate the risk factors of cardiovascular and cerebrovascular events in diabetes patients, and built the first risk prediction model of cardiovascular and cerebrovascular events in diabetes patients based on the Chinese population follow-up queue and externally verified, so as to identify high-risk groups and guide the early prevention of cardiovascular and cerebrovascular diseases in diabetes patients. To evaluate the effect of incretin drugs on reducing the risk of cardiovascular and cerebrovascular events, and the impact on the remission rate of diabetes in people with initial diabetes, a randomized, multicenter, controlled clinical study was conducted. The long-term follow-up of 2 years was conducted to evaluate whether the cardiovascular and cerebrovascular risks of those who stopped drug treatment after remission of diabetes compared with those who continued drug treatment were reduced, as well as the long-term impact of incretin on cardiovascular and cerebrovascular risks and the role of long-term mitigation of diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06959784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of semaglutide
Trials testing the same drug.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
- NCT07466017 — A Study of CS060380 Tablets in Patients With MASH and Obesity · Phase 2 · recruiting
- NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
- NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
Other recruiting trials for Diabetes Mellitus
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
- NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
- NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting
Other China-Japan Friendship Hospital trials
Trials by the same sponsor.
- NCT07482995 — Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults · NA · not yet recruiting
- NCT07406932 — A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial L · NA · not yet recruiting
- NCT07509775 — Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on · recruiting
- NCT07339956 — Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents · EARLY_PHASE1 · not yet recruiting
- NCT07280429 — ICIAM Rehabilitation Program Study: A Randomized Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06959784 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China-Japan Friendship Hospital
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06959784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing